A dedicated microarray for in-depth analysis of pre-mRNA splicing events: Application to the study of genes involved in the response to targeted anticancer therapies

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Pesson, Marine ^a   Eymin, Béatrice ^b   De La Grange, Pierre ^c   Simon, Brigitte ^a   Corcos, Laurent ^a  

^a FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

DNA chip; Pre mRNA splicing; SRSF2; Targeted anticancer therapies

Indexed keywords

GEFITINIB; MESSENGER RNA; MESSENGER RNA PRECURSOR; PROTEIN; SRSF2 PROTEIN; UNCLASSIFIED DRUG;

AKT1 GENE; AKT2 GENE; AKT3 GENE; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA MICROARRAY; EXON; GENE OVEREXPRESSION; GENE PROBE; GENE STRUCTURE; GENETIC ENGINEERING; HER1 GENE; HER2 GENE; HER3 GENE; HER4 GENE; HIF1A GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MOLECULARLY TARGETED THERAPY; PIK3CA GENE; PIK3R1 GENE; PIK3R2 GENE; PIR GENE; RNA STRUCTURE; TUMOR GENE; VEGFA GENE; VEGFB GENE; VEGFC GENE; VEGFD GENE;

ADENOCARCINOMA; ALTERNATIVE SPLICING; BLOTTING, WESTERN; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RIBONUCLEOPROTEINS; RNA PRECURSORS;

EID: 84892900538     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-9     Document Type: Article

References (48)

1. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456:470-476. 10.1038/nature07509, 2593745, 18978772.
2. Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature 2010, 463:457-463. 10.1038/nature08909, 3443858, 20110989.
3. Dutertre M, Sanchez G, De Cian M-C, Barbier J, Dardenne E, Gratadou L, Dujardin G, Le Jossic-Corcos C, Corcos L, Auboeuf D. Cotranscriptional exon skipping in the genotoxic stress response. Nat Struct Mol Biol 2010, 17:1358-1366. 10.1038/nsmb.1912, 20972445.
4. Hallegger M, Llorian M, Smith CWJ. Alternative splicing: global insights. FEBS J 2010, 277:856-866. 10.1111/j.1742-4658.2009.07521.x, 20082635.
5. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010, 24:2343-2364. 10.1101/gad.1973010, 2964746, 21041405.
6. Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004, 61:2189-2199.
7. Miura K, Fujibuchi W, Unno M. Splice variants in apoptotic pathway. Exp Oncol 2012, 34:212-217.
8. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005, 19:1-13. 10.1016/j.molcel.2005.05.026, 15989960.
9. Maquat LE. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol Cell Biol 2004, 5:89-99. 10.1038/nrm1310, 15040442.
10. Isken O, Maquat LE. The multiple lives of NMD factors: balancing roles in gene and genome regulation. Nat Rev Genet 2008, 9:699-712. 10.1038/nrg2402, 3711694, 18679436.
11. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, Veitch J, Schweitzer A, Awad T, Sugnet C, Dee S, et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006, 7:325. 10.1186/1471-2164-7-325, 1769375, 17192196.
12. Mojica W, Hawthorn L. Normal colon epithelium: a dataset for the analysis of gene expression and alternative splicing events in colon disease. BMC Genomics 2010, 11:5. 10.1186/1471-2164-11-5, 2823691, 20047688.
13. Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett 2012, 340:248-295.
14. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009, 10:57-63. 10.1038/nrg2484, 2949280, 19015660.
15. Mutz K-O, Heilkenbrinker A, Lönne M, Walter J-G, Stahl F. Transcriptome analysis using next-generation sequencing. Curr Opin Biotechnol 2013, 24:22-30. 10.1016/j.copbio.2012.09.004, 23020966.
16. Lindner R, Friedel CC. A comprehensive evaluation of alignment algorithms in the context of RNA-Seq. PLoS ONE 2012, 7:e52403. 10.1371/journal.pone.0052403, 3530550, 23300661.
17. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol 2012, 31:46-53. 10.1038/nbt.2450, 3869392, 23222703.
18. Xu W, Seok J, Mindrinos MN, Schweitzer AC, Jiang H, Wilhelmy J, Clark TA, Kapur K, Xing Y, Faham M, et al. Human transcriptome array for high-throughput clinical studies. Proc Natl Acad Sci 2011, 108:3707-3712. 10.1073/pnas.1019753108, 3048146, 21317363.
19. Glas AM, Floore A, Delahaye LJMJ, Witteveen AT, Pover RCF, Bakx N, Lahti-Domenici JST, Bruinsma TJ, Warmoes MO, Bernards R, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006, 7:278. 10.1186/1471-2164-7-278, 1636049, 17074082.
20. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684. 10.1056/NEJMoa052122, 16236738.
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672. 10.1056/NEJMoa052306, 16236737.
22. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 1998, 6:1153-1167. 10.1016/S0969-2126(98)00116-6, 9753694.
23. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001, 114:853-865.
24. Bates DO, Cui T-G, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002, 62:4123-4131.
25. Ladomery MR, Harper SJ, Bates DO. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett 2007, 249:133-142. 10.1016/j.canlet.2006.08.015, 17027147.
26. Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, Brambilla C, Brambilla E, Gazzeri S, Eymin B. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 2010, 29:5392-5403. 10.1038/onc.2010.281, 20639906.
27. Lin S, Coutinho-Mansfield G, Wang D, Pandit S, Fu X-D. The splicing factor SC35 has an active role in transcriptional elongation. Nat Struct Mol Biol 2008, 15:819-826. 10.1038/nsmb.1461, 2574591, 18641664.
28. Gout S, Brambilla E, Boudria A, Drissi R, Lantuejoul S, Gazzeri S, Eymin B. Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PLoS ONE 2012, 7:e46539. 10.1371/journal.pone.0046539, 3468597, 23071587.
29. Wang J, Manley JL. Overexpression of the SR proteins ASF/SF2 and SC35 influences alternative splicing in vivo in diverse ways. RNA 1995, 1:335-346. 1369086, 7489505.
30. Wang X, Cairns MJ. Gene set enrichment analysis of RNA-Seq data: integrating differential expression and splicing. BMC Bioinforma 2013, 14:S16.
31. Ma X, Zhang X. NURD: an implementation of a new method to estimate isoform expression from non-uniform RNA-seq data. BMC Bioinforma 2013, 14:220.
32. Rahman FA, Aziz N, Coverley D. Differential detection of alternatively spliced variants of Ciz1 in normal and cancer cells using a custom exon-junction microarray. BMC Cancer 2010, 10:482. 10.1186/1471-2407-10-482, 2945943, 20831784.
33. Bates DO, Harper SJ. Therapeutic potential of inhibitory VEGF splice variants. Future Oncol 2005, 1:467-473. 10.2217/14796694.1.4.467, 16556023.
34. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat Rev Cancer 2008, 8:880-887. 10.1038/nrc2505, 2613352, 18923433.
35. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, Bates DO. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 2010, 285:5532-5540. 10.1074/jbc.M109.074930, 2820781, 19906640.
36. Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO. The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans 2009, 37:1207-1213. 10.1042/BST0371207, 2882696, 19909248.
37. Hilmi C, Guyot M, Pages G. VEGF spliced variants: possible role of anti-angiogenesis therapy. J Nucleic Acids 2012, 2012:162692. 3195439, 22013509.
38. Guillaudeau A, Durand K, Bessette B, Chaunavel A, Pommepuy I, Projetti F, Robert S, Caire F, Rabinovitch-Chable H, Labrousse F. EGFR soluble isoforms and their transcripts are expressed in meningiomas. PLoS One 2012, 7:e37204. 10.1371/journal.pone.0037204, 3356382, 22623992.
39. Wang H, Zhou M, Shi B, Zhang Q, Jiang H, Sun Y, Liu J, Zhou K, Yao M, Gu J, et al. Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 2011, 13:461-471. 3084623, 21532887.
40. Imielinski M, Berger Alice H, Hammerman Peter S, Hernandez B, Pugh Trevor J, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120. 10.1016/j.cell.2012.08.029, 3557932, 22980975.
41. Varey AHR, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, Dixon AR, Paraskeva C, Zaccheo O, Hassan AB, et al. VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 2008, 98:1366-1379. 10.1038/sj.bjc.6604308, 2361696,2361696, 18349829.
42. Lagarrigue M, Alexandrov T, Dieuset G, Perrin A, Lavigne R, Baulac S, Thiele H, Martin B, Pineau C. New analysis workflow for MALDI imaging mass spectrometry: application to the discovery and identification of potential markers of childhood absence epilepsy. J Proteome Res 2012, 11:5453-5463. 10.1021/pr3006974, 22994238.
43. Solier S, Lansiaux A, Logette E, Wu J, Soret J, Tazi J, Bailly C, Desoche L, Solary E, Corcos L. Topoisomerase I and II inhibitors control caspase-2 Pre-Messenger RNA splicing in human cells. Mol Cancer Res 2004, 2:53-61.
44. Salon C, Eymin B, Micheau O, Chaperot L, Plumas J, Brambilla C, Brambilla E, Gazzeri S. E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIPshort. Cell Death Differ 2006, 13:260-272. 10.1038/sj.cdd.4401739, 16052233.
45. Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S, Eymin B. E2F1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 2007, 26:6927-6936. 10.1038/sj.onc.1210499, 17471231.
46. Gandoura S, Weiss E, Rautou P-E, Fasseu M, Gustot T, Lemoine F, Hurtado-Nedelec M, Hego C, Vadrot N, Elkrief L. Gene-and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. J Hepatol 2013, 58:936-948. 10.1016/j.jhep.2012.12.025, 23321315.
47. Wang E, Aslanzadeh V, Papa F, Zhu H, de la Grange P, Cambi F. Global profiling of alternative splicing events and gene expression regulated by hnRNPH/F. PLoS ONE 2012, 7:e51266. 10.1371/journal.pone.0051266, 3524136, 23284676.
48. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 - ΔΔCT method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.